Market Place
Sourcing Support
Ractigen Founder Dr. Long-Cheng Li Wins Life Science Award
31 Dec 2024 //
PR NEWSWIRE
Ractigen Therapeutics Doses 1st Patient in Phase I Trial for RAG-17
24 Dec 2024 //
PR NEWSWIRE
Ractigen Wins FDA Orphan Drug Designation for RAG-21 in ALS
19 Nov 2024 //
PR NEWSWIRE
Ractigen Announces Positive RAG-17 ALS-SOD1 Trial Data
10 Sep 2024 //
PR NEWSWIRE
Ractigen`s RAG-18 Gets FDA Orphan Drug Designation For DMD/BMD
22 Aug 2024 //
PR NEWSWIRE
Ractigen`s RAG-18 Gets FDA Rare Pediatric Disease Designation
25 Jul 2024 //
PR NEWSWIRE
Ractigen Gets FDA Fast Track For RAG-01 saRNA Therapy
21 May 2024 //
PR NEWSWIRE
Ractigen`s RAG-17 For SOD1-ALS Receives China IND Approval
15 May 2024 //
PR NEWSWIRE
Ractigen Enters Strategic Partnership with University Medical Center Utrecht
29 Jan 2024 //
PR NEWSWIRE
Ractigen Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
06 Dec 2023 //
GLOBENEWSWIRE
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD
02 Nov 2023 //
GLOBENEWSWIRE
Ractigen Announces Dosing of First Patient in First in Human Trial of RAG-17
05 Jun 2023 //
GLOBENEWSWIRE
Ractigen Therapeutics Receives FDA Orphan Drug Designation for RAG-17
03 Mar 2023 //
GLOBENEWSWIRE
Ractigen Therapeutics Announces the Appointment of Harri Jarvelainen as COO
09 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.